apart from [0.1:99%) through renal excretion, nearly exclusively as pivaloylcarnitine. Following a 200 mg BID regimen for 10 days, the mean decrease in plasma concentrations of total carnitine was 18.1 7.2 nmole/mL, representing a 39% decrease in plasma carnitine concentrations. Following a 400 mg BID regimen for 14 days, the mean decrease in plasma concentrations of carnitine was 33.3 9.7 nmole/mL, representing a 63% decrease in plasma carnitine concentrations. Plasma concentrations of carnitine returned to the normal control range within 7 to 10 days after discontinuation of Cefditoren Pivoxil. (See PRECAUTIONS , General and CONTRAINDICATIONS .) Special Populations Geriatric The effect of age on the pharmacokinetics of cefditoren was evaluated in 48 male and female subjects aged 25 to 75 years given 400 mg Cefditoren Pivoxil BID for 7 days. Physiological changes related to increasing age increased the extent of cefditoren exposure in plasma, as evidenced by a 26% higher C max and a 33% higher AUC for subjects aged 65 years compared with younger subjects. The rate of elimination of cefditoren from plasma was lower in subjects aged 65 years, with t 1/2 values 16-26% longer than for younger subjects. Renal clearance of cefditoren in subjects aged 65 years was 20-24% lower than in younger subjects. These changes could be attributed to age-related changes in creatinine clearance. No dose adjustments are necessary for elderly patients with normal (for their age) renal function. Gender The effect of gender on the pharmacokinetics of cefditoren was evaluated in 24 male and 24 female subjects given 400 mg Cefditoren Pivoxil BID for 7 days. The extent of exposure in plasma was greater in females than in males, as evidenced by a 14% higher C max and a 16% higher AUC for females compared to males. Renal clearance of cefditoren in females was 13% lower than in males. These differences could be attributed to gender-related differences in lean body mass. No dose adjustments are necessary for gender. Renal Insufficiency Cefditoren pharmacokinetics were investigated in 24 adult subjects with varying degrees of renal function following administration of Cefditoren Pivoxil 400 mg BID for 7 days. Decreased creatinine clearance (CL cr ) was associated with an increase in the fraction of unbound cefditoren in plasma and a decrease in the cefditoren elimination rate, resulting in greater systemic exposure in subjects with renal impairment. The unbound C max and AUC were similar in subjects with mild renal impairment (CL cr : 50-80 mL/min/1.73 m 2 ) compared to subjects with normal renal function (CL cr : >80 mL/min/1.73 m 2 ). Moderate (CL cr : 30-49 mL/min/1.73 m 2 ) or severe (CL cr :] FEATURED: CAR-T Cell Therapy Overview Mechanism of Action KTE-C19 Studies KTE-C19 Cancer Targets Adverse Events Manufacturing Drug Status Rx Availability Prescription only B Pregnancy Category No proven risk in humans N/A CSA Schedule Not a controlled drug Approval History Drug history at FDA Drug Class Third generation cephalosporins Related Drugs third generation cephalosporins cefdinir , ceftriaxone , Rocephin , Omnicef , cefpodoxime , cefixime Skin or Soft Tissue Infection ciprofloxacin , amoxicillin , azithromycin , doxycycline , cephalexin , More... Pneumonia ciprofloxacin , amoxicillin , azithromycin , doxycycline , metronidazole , More... Skin and Structure Infection ciprofloxacin , azithromycin , Augmentin , Zithromax , cefdinir , More... 2 more conditions... Cefditoren Rating 4 User Reviews 3.5 /10 4 User Reviews 3.5 Rate it! charges
deadlock Cefditoren Pivoxil is certain
EmoticonEmoticon